Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 16:35:04 30/04/2024 BST			After market 18:31:10
27.97 ^EUR	+1.05%		27.84	-0.48%

04-29	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	MT
04-26	FRESENIUS SE : Jefferies reiterates its Buy rating	ZD

FRESENIUS SE : Barclays reiterates its Buy rating

September 10, 2021 at 07:52 am

Barclays analyst Hassan Al-Wakeel maintains his Buy rating on the stock. The target price has been lifted and is now set at EUR 53 compared to EUR 51 before.

Latest news about Fresenius SE & Co. KGaA

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	04-29	MT
FRESENIUS SE : Jefferies reiterates its Buy rating	04-26	ZD
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	04-24	MT
FRESENIUS SE : Warburg Research reiterates its Buy rating	04-24	ZD
FRESENIUS SE : Goldman Sachs sticks Neutral	04-23	ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA.	04-22	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	04-22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	04-22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	04-22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	04-22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	04-22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	04-22	ZD
Positive trend of FMC and Fresenius continues	04-22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	04-18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	04-17	DP
State report warns of risks in hospital reform	04-17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	04-17	ZD
Warnings against cutbacks in hospital reform	04-17	DP
Federal and state governments to discuss hospital reform again	04-17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	04-16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	04-16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	04-16	DP
Fresenius at two-month high - Tyenne launch a milestone	04-16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	04-15	MT
Cannabis law and clinic atlas in the Bundesrat	03-22	DP

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

07/05/2024 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 12:42 pm

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.68 EUR

Average target price

36.22 EUR

Spread / Average Target

+30.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-0.36%	16.7B
CVS HEALTH CORPORATION	-14.45%	85.02B
HCA HEALTHCARE, INC.	+14.42%	82.37B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.29B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.34%	17.21B
QUEST DIAGNOSTICS INCORPORATED	+1.05%	15.5B
FRESENIUS MEDICAL CARE AG	+4.32%	12.15B
EUROFINS SCIENTIFIC SE	-2.34%	12.13B
DAVITA INC.	+31.80%	12.12B
PURE HEALTH HOLDING	-31.05%	11.8B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Barclays reiterates its Buy rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services